ArticleFrontiers in genetics2024
Subtyping colorectal cancer based on septic shock-associated genes: prognosis and immune characteristics.
Article in Frontiers in genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of CD4_Naive cells related gene FMO4 as a positive regulator of the poor prognosis of septic CRC patients.Cancer cell international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis and colorectal cancer (CRC) are leading causes of death. Given their mutual dependence for susceptibility, we used bioinformatics to explore potential connections between septic shock (SS) and CRC. Methods: We identified 452 co-expressed genes between SS-related differential expression genes (SS-DEGs) and CRC patient-expressed genes (TCGA-CRC genes). CRC samples were categorized into two cluster subgroups through hierarchical clustering. We then compared the prognosis and immune landscapes of the two cluster subgroups through survival analysis, immune microenvironment analysis, and immune therapy response evaluation. Results: Clustering analysis of the 452 CRC patient-expressed SS-DEGs identified two subtypes: SS-like CRC (SL-CRC) and non-SS-like CRC (NSL-CRC). There were no significant differences in overall survival between the CRC subtypes. However, the subtypes displayed significant differences in immune score, stromal score, and ESTIMATE score. Based on immune therapy databases, there were also significant differences in responses to anti-CTLA-4 and anti-PD-1 immune checkpoint inhibitors between the subtypes. Conclusion: Our study reveals significant differences in the immune microenvironment and immune therapy responses between SL-CRC and NSL-CRC subtypes. These findings provide a foundation for identifying new therapeutic targets and developing personalized treatment strategies for specific CRC subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.